Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OCP + metformin refers to the combination therapy of a combined oral contraceptive pill (COCP or OCP) and the insulin-sensitizing agent metformin. This regimen is primarily used in the management of polycystic ovary syndrome (PCOS), targeting both hyperandrogenism and metabolic disturbances such as insulin resistance. Oral contraceptives act by suppressing ovarian androgen production through inhibition of gonadotropin secretion, while metformin improves insulin sensitivity by inhibiting hepatic gluconeogenesis and enhancing peripheral glucose uptake. The combination aims to address both hormonal imbalances (e.g., hirsutism, menstrual irregularity) and metabolic dysfunctions (e.g., impaired glucose tolerance) seen in PCOS. Clinical studies suggest that this combination may offer additional benefits over monotherapy for certain metabolic outcomes but with variable effects on weight, menstrual regulation, and androgen levels[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ocp + metformin.